Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines.

Thayanithy V, Park C, Sarver AL, Kartha RV, Korpela DM, Graef AJ, Steer CJ, Modiano JF, Subramanian S.

PLoS One. 2012;7(9):e43720. doi: 10.1371/journal.pone.0043720. Epub 2012 Sep 5.


Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.

Phillip CJ, Giardina CK, Bilir B, Cutler DJ, Lai YH, Kucuk O, Moreno CS.

BMC Cancer. 2012 Apr 11;12:145. doi: 10.1186/1471-2407-12-145.


Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.

Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP.

Int J Cancer. 2007 Aug 1;121(3):656-65.


Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.

Thayanithy V, Sarver AL, Kartha RV, Li L, Angstadt AY, Breen M, Steer CJ, Modiano JF, Subramanian S.

Bone. 2012 Jan;50(1):171-81. doi: 10.1016/j.bone.2011.10.012. Epub 2011 Oct 18.


Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.

Billam M, Sobolewski MD, Davidson NE.

Breast Cancer Res Treat. 2010 Apr;120(3):581-92. doi: 10.1007/s10549-009-0420-3. Epub 2009 May 21.


Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.

Suzuki M, Shinohara F, Nishimura K, Echigo S, Rikiishi H.

Int J Oncol. 2007 Dec;31(6):1449-56.


Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.

Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF.

Exp Hematol. 2007 Feb;35(2):263-73.


Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.

J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.


Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.

Wu Z, Ma C, Shan Z, Ju Y, Li S, Zhao Q.

J BUON. 2013 Oct-Dec;18(4):1032-7.


The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.

Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH.

Cancer Chemother Pharmacol. 2011 Jan;67(1):83-92. doi: 10.1007/s00280-010-1287-z. Epub 2010 Mar 20.


Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.

Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN.

J Cell Biochem. 2004 May 15;92(2):223-37.


Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.

Kisseberth WC, Murahari S, London CA, Kulp SK, Chen CS.

Am J Vet Res. 2008 Jul;69(7):938-45. doi: 10.2460/ajvr.69.7.938.


Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Richon VM, Sandhoff TW, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9.


Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.

Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R.

Mol Cancer Ther. 2007 Jan;6(1):70-81.


Epigenetic therapy of cancer with histone deacetylase inhibitors.

Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC.

J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937. Review.


A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.

Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.

PLoS One. 2010 Sep 14;5(9):e12417. doi: 10.1371/journal.pone.0012417.


Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.

Osada H, Tatematsu Y, Sugito N, Horio Y, Takahashi T.

Mol Carcinog. 2005 Dec;44(4):233-41.


Zebularine enhances apoptosis of human osteosarcoma cells by suppressing methylation of ARHI.

Ye K, Wang S, Wang J, Han H, Ma B, Yang Y.

Cancer Sci. 2016 Dec;107(12):1851-1857. doi: 10.1111/cas.13088. Epub 2016 Dec 19.


Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.

Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, Lee SM, Lee SJ, Park IC, Jin YW, An S.

Int J Mol Med. 2009 Jul;24(1):45-50.


The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.

Mu X, Brynien D, Weiss KR.

Biomed Res Int. 2015;2015:290368. doi: 10.1155/2015/290368. Epub 2015 Feb 17.

Supplemental Content

Support Center